The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 1 November 2005, www.theannals.com, DOI 10.1345/aph.1G239.
 The Annals of Pharmacotherapy: Vol. 39, No. 12, pp. 2081-2085. DOI 10.1345/aph.1G239
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chilson, C. N
Right arrow Articles by Brown, S. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chilson, C. N
Right arrow Articles by Brown, S. J

DRUG INFORMATION ROUNDS

Role of Botulinum Toxin Type A in the Prophylactic Treatment of Migraine Headaches

Crystal N Chilson, PharmD1, and Sherrill J Brown, DVM PharmD2

1 Student, Skaggs School of Pharmacy, University of Montana, Missoula, MT
2 Director of Drug Information, Skaggs School of Pharmacy, University of Montana

Reprints: Ms. Chilson, 4440 Edinburgh Dr., Anchorage, AK 99502-1419, fax 907/522-2127, crystinichole{at}gmail.com

OBJECTIVE: To evaluate the role of botulinum toxin type A in the prophylaxis of migraine headaches.

DATA SOURCES: MEDLINE (1966-July 2005), Iowa Drug Information Service (1966-July 2005), and International Pharmaceutical Abstracts (1970-July 2005) searches were performed. Key search terms included botulinum and migraine.

DATA SYNTHESIS: Patients who received botulinum toxin type A injections for treatment of hyperfunctional facial lines also experienced relief of migraine symptoms, leading to further investigation. Four clinical trials and 2 retrospective chart reviews evaluating the use of botulinum toxin type A injections for the prophylactic treatment of migraines are discussed. Limitations of these trials include problems with blinding, use of different injection sites, and inconsistent dosing.

CONCLUSIONS: The results of 3 double-blind, placebo-controlled trials, 2 retrospective chart reviews, and an open-label study indicate that botulinum toxin type A may be a safe and efficacious prophylactic treatment for migraine headaches.

Key Words: botulinum toxin A, migraine headache

Published Online, November 1, 2005. www.theannals.com, DOI 10.1345/aph.1G239


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
L. S Eiland, L. S Jenkins, and S. H Durham
Pediatric Migraine: Pharmacologic Agents for Prophylaxis
Ann. Pharmacother., July 1, 2007; 41(7): 1181 - 1190.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.